Last reviewed · How we verify
Placebo for etanercept subcutaneous injection
This drug is a placebo for etanercept subcutaneous injection, meaning it has no active therapeutic effect.
This drug is a placebo for etanercept subcutaneous injection, meaning it has no active therapeutic effect. Used for Treatment of moderate to severe rheumatoid arthritis.
At a glance
| Generic name | Placebo for etanercept subcutaneous injection |
|---|---|
| Sponsor | Amgen |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it does not interact with any molecular targets or receptors, and its primary purpose is to serve as a control in clinical trials for etanercept. This allows researchers to compare the efficacy and safety of etanercept to a treatment with no active ingredients.
Approved indications
- Treatment of moderate to severe rheumatoid arthritis
Common side effects
- Injection site reaction
Key clinical trials
- A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs (PHASE3)
- Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis (PHASE3)
- Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet (PHASE1, PHASE2)
- Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission (PHASE3)
- Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis (PHASE3)
- A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012) (PHASE3)
- Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) (PHASE3)
- A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for etanercept subcutaneous injection CI brief — competitive landscape report
- Placebo for etanercept subcutaneous injection updates RSS · CI watch RSS
- Amgen portfolio CI